Key facts
- This page summarizes Nathaniel Calloway's Form 4 filing for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 02 Feb 2023, 16:30.
Nathaniel Calloway - 01 Feb 2023 Form 4 Insider Report for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)
- Reporting relationship
- Director
- Issuer ticker
- LFCR
- Reported as of
- 01 Feb 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Feb 2023, 16:30:26 UTC
- Prior SEC filing
- 11 Jan 2023
- Next SEC filing
- 05 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/Aaron Perlitsh
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Nathaniel Calloway filed Form 4 for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) on 02 Feb 2023.
Change
- Previous filing in this sequence was filed on 11 Jan 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LFCR
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- Shares
- +3,981
- Change %
- Price
- Shares after
- 3,981
- Date
- 01 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,981
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The Restricted Stock Units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
Footnote F2
Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock.